Alzheimer's Disease Drug Development Pipeline: March 31, 2026

Therapeutic Landscape Table

Data Readouts

Troculeucel — NKGen Biotech

Troculeucel is an autologous, ex vivo-expanded natural killer (NK) cell immunotherapeutic being developed for moderate Alzheimer's disease. NKGen presented pooled analyses from two previously completed open-label Phase 1 studies (NCT04678453; NCT06189963) at AD/PD™ 2026 on March 23, 2026. ^[3]

Phase 1 Pooled Analysis — Moderate AD Cognitive Outcomes: 100% stable or improved; 50% improved from moderate to mild (CDR-SB)

In a focused analysis of moderate AD patients (n=6) across dose levels ranging from 1 to 6 billion cells, all patients were stable or improved at three months across all established MCID thresholds: ADAS-Cog (±4 points), CDR-SB (±2 points), and ADCOMS (±0.1 points). Higher doses (4–6B cells) were associated with greater directional improvement and more frequent MCID exceedance. 50% of patients improved from the moderate to mild range on CDR-SB. Importantly, no cognitive decline was observed in any patient, a striking finding given the typically rapid rate of decline in moderate-stage disease. Two patients followed for 12 months maintained their improvements, providing early durability signals. Troculeucel was very well tolerated with no treatment-related adverse events.

Plasma GFAP Biomarker Correlations: Strong and consistent associations with cognitive status at baseline and follow-up

In a separate poster presentation, NKGen reported that plasma GFAP correlated significantly with CDR-SB (r=0.60, p=0.044) and ADCOMS (r=0.64, p=0.030) at baseline, and that these correlations remained robust after three months of treatment. In the higher-dose subgroup (≥4B cells), correlations strengthened further: CDR-SB r=0.76 (p=0.009) and ADCOMS r=0.71 (p=0.018). Pooled longitudinal analyses reinforced these findings (CDR-SB r=0.56, p=0.001; ADCOMS r=0.50, p=0.004), supporting plasma GFAP as a reliable, non-invasive biomarker of neuroinflammation and clinical status in this population.

These results come from small, open-label Phase 1 studies without a control arm, and should be interpreted accordingly. The ongoing Phase 2 trial in moderate AD is actively enrolling and will provide the first controlled evidence.

Trial Updates

Buntanetap — Annovis Bio

Buntanetap (formerly Posiphen) is an oral, once-daily investigational translation inhibitor that reduces production of amyloid precursor protein (APP), alpha-synuclein, and tau by targeting 5'UTR iron-responsive elements in their mRNA. A Phase 2b dose-ranging study in mild-to-moderate AD (NCT05686044) demonstrated statistically significant cognitive improvement in plasma pTau217-positive patients with mild AD, with supporting biomarker findings showing reductions in neurotoxic aggregation proteins, decreased inflammation, and improved neuronal function. These results supported initiation of a pivotal Phase 3 trial in April 2025. ^[4]

Phase 3 Enrollment Update: 760 participants targeted; 83 US sites; dual readouts at 6 and 18 months

At AD/PD™ 2026, Annovis Bio presented an enrollment update for the ongoing Phase 3 buntanetap study (NCT06709014) in early AD. The prospective, double-blind, randomized, placebo-controlled trial targets 760 participants across 83 US sites. The dual-readout design will evaluate symptomatic effects at 6 months and disease-modifying effects at 18 months, an innovative structure that could provide earlier commercial readout while the longer-term disease modification data mature. The poster reported updates on site activation status, screening procedures, screen failure rates, enrollment pace, and projected database lock timeline. Specific enrollment numbers were not disclosed in the abstract.

PMN310 — ProMIS Neurosciences

PMN310 is a humanized IgG1 monoclonal antibody selectively targeting toxic amyloid-beta oligomers (AβO) while avoiding amyloid plaque, a design intended to preserve anti-oligomer biological activity while eliminating the plaque-binding mechanism hypothesized to drive ARIA. PMN310 received FDA Fast Track Designation in July 2025. The PRECISE-AD Phase 1b study (NCT06750432) is a randomized, double-blind, placebo-controlled multiple ascending dose study evaluating 5, 10, and 20 mg/kg IV PMN310 in patients with MCI due to AD or mild AD. ^[5]

PRECISE-AD Enrollment Complete: 144 participants enrolled (vs. 128 target); DSMB cleared highest dose cohort

On March 25, 2026, ProMIS announced that PRECISE-AD enrollment was completed in December 2025, with 144 participants enrolled, 12.5% above the 128-patient target. The overenrollment was characterized by management as reflecting meaningful clinical interest in PMN310's differentiated mechanism. The Data and Safety Monitoring Board reviewed safety data and recommended advancement to Cohort 3 (the highest planned dose level, 20 mg/kg) with no safety concerns identified. To date, no treatment-related serious adverse events have been reported. Six-month blinded safety and biomarker data are expected in Q3 2026; top-line unblinded data are anticipated in early 2027 following completion of all patient visits, database lock, and statistical analysis.

ProMIS closed a $75.5 million private placement in February 2026, providing cash runway through 2027 and funding an accelerated subcutaneous formulation development program for PMN310, a competitive positioning move ahead of potential Phase 2 design discussions.

PrimeC — NeuroSense Therapeutics

PrimeC is a novel extended-release oral formulation comprising a fixed-dose combination of two FDA-approved drugs (ciprofloxacin and celecoxib) developed by NeuroSense Therapeutics Ltd. (NASDAQ: NRSN). The compound targets multiple mechanisms associated with neurodegenerative diseases, including neuron degeneration, inflammation, iron accumulation, and impaired RNA regulation. NeuroSense is advancing PrimeC across two indications: ALS (lead program) and Alzheimer's disease. ^[7]

Alzheimer's Disease Program: Clinical and biomarker results expected in coming weeks

On March 24, 2026, NeuroSense disclosed that it expects to report clinical and biomarker results from its Alzheimer's disease study in the coming weeks. No trial identifier, sample size, endpoint structure, dose information, or specific timeline within the "coming weeks" window was provided.

The same announcement also contained an ALS-specific regulatory update (Health Canada pre-NDS rescheduling), which is covered separately under Regulatory Updates below.

Regulatory Updates

Blarcamesine — Anavex Life Sciences

Blarcamesine (ANAVEX®2-73) is an oral, once-daily investigational sigma-1 receptor (SIGMAR1) and muscarinic receptor modulator in development for early Alzheimer's disease. The compound has completed a Phase 2a and a Phase 2b/3 clinical trial for AD, with the latter serving as the basis for Anavex's EU regulatory submission. ^[2]

EMA Regulatory Outcome: Marketing authorization application withdrawn

On March 25, 2026, Anavex announced withdrawal of its EU marketing authorization application for blarcamesine following feedback from the EMA's Committee for Medicinal Products for Human Use (CHMP) indicating it would not be in a position to issue a positive opinion. Anavex noted it had originally submitted following encouragement from the EMA's SME Office in October 2023, making the CHMP's differing assessment a material reversal. The company stated it will consider the CHMP's constructive feedback, focus on additional data and analyses, and continue engagement with regulatory authorities. No corresponding US NDA has been filed.

The withdrawal does not terminate blarcamesine's clinical development; Anavex remains committed to the program and cited strong patient and advocacy group support, including from Alzheimer Europe. However, it removes the near-term path to approval in the EU and raises questions about the sufficiency of Phase 2b/3 data for regulatory purposes. The SIGMAR1 mechanism has not yet been validated in a successful registrational trial in any indication.

PrimeC / Health Canada pre-NDS — NeuroSense Therapeutics (ALS program)

Note: This event relates to PrimeC's ALS program, not its Alzheimer's disease program. It is covered here because PrimeC is the same asset in active AD development, and regulatory progress in any indication has direct implications for the compound's overall development trajectory and clinical strategy.

PrimeC has demonstrated a statistically significant 65% reduction in risk of death in ALS and received FDA clearance to initiate the pivotal Phase 3 PARAGON trial. NeuroSense is pursuing approval for PrimeC in Canada under the NOC/c pathway, which is designed to facilitate earlier access to therapies addressing serious unmet medical needs. ^[7]

Health Canada pre-NDS Meeting Rescheduled: May 2026; strengthened data package under assembly

On March 24, 2026, NeuroSense announced that its pre-New Drug Submission (pre-NDS) meeting with Health Canada has been rescheduled to May 2026. The decision was made to allow for the inclusion of additional emerging clinical, biomarker, and survival data and analyses in the briefing package, which the company believes will meaningfully strengthen the scientific and clinical foundation supporting PrimeC. The original meeting timing was not disclosed.

Funding / BD Activity

EBD Program — Acumen Pharmaceuticals

Acumen Pharmaceuticals (NASDAQ: ABOS) is a clinical-stage biopharmaceutical company developing amyloid beta oligomer (AβO)-selective therapeutics for Alzheimer's disease. Its lead clinical asset, sabirnetug (ACU193), is a humanized monoclonal antibody currently in Phase 2 (ALTITUDE-AD trial) that selectively targets toxic soluble AβOs. In July 2025, Acumen announced a collaboration with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD™) program pairing AβO-selective antibodies with JCR's J-Brain Cargo® blood-brain barrier-penetrating technology, which facilitates CNS entry through transferrin-receptor (TfR)-mediated transcytosis. ^[1]

NHP Preclinical Data: 14–40x brain exposure vs. native antibodies; low anemia risk; subcutaneous dosing compatible

On March 16, 2026, Acumen disclosed preclinical data for its EBD development candidates, including in vitro, in vivo murine, and non-human primate (NHP) results. Key findings: (1) Brain penetration: development candidates achieved 14–40x higher brain levels in NHPs versus native antibodies at 24 hours post-dose, a result Acumen characterized as exceeding its target profile, with consistent and predictive results across in vitro and in vivo species. (2) Anemia risk: hematology data in NHPs showed no adverse effects, indicating low potential for anemia, directly addressing the canonical safety concern for TfR-targeting approaches, since transferrin receptor is expressed on erythroid progenitor cells and high-affinity TfR binding can cause dose-dependent anemia. (3) Subcutaneous dosing: the candidates demonstrated a favorable stability profile compatible with subcutaneous administration via low-volume devices, a meaningful commercial and patient convenience advantage over IV-administered anti-amyloid antibodies currently on the market.

$35.75 Million Private Placement: RA Capital-led; IND targeted mid-2027

Concurrent with the data disclosure, Acumen entered into a securities purchase agreement for a $35.75 million private placement at $3.30 per share, closing on approximately March 16, 2026. The financing was led by existing investor RA Capital Management with participation from ADAR1 Capital Management, Sands Capital, and a large undisclosed investment management firm. Proceeds are primarily designated for ongoing EBD preclinical development to support nomination of a lead clinical candidate molecule. An IND submission for the lead EBD candidate is targeted for mid-2027.

The EBD program's differentiation relative to sabirnetug itself lies entirely in brain exposure: standard monoclonal antibodies cross the blood-brain barrier at less than 0.1–0.5% of serum concentration, while the EBD candidates with J-Brain Cargo® achieved dramatically higher CNS levels in NHPs. If this translates to humans, it could allow effective target engagement at lower systemic doses or enable patient populations where BBB permeability is further compromised. Acumen's management characterizes the program as the only EBD approach in the anti-amyloid space that pairs an AβO-targeting antibody with a validated TfR-targeting technology, a claim that, if accurate at IND, would represent a structurally distinct competitive position from currently approved anti-amyloid antibodies and from other oligomer-selective programs such as PMN310.

Investor profiles — Acumen $35.75M private placement: The financing is structured as a PIPE (private investment in public equity) at $3.30/share. RA Capital Management (lead, existing investor) is a Boston-based healthcare-focused investment firm that manages a multi-billion dollar long/short equity fund and a dedicated venture fund (Nexus); the firm invests across biotech, medtech, and healthcare services at all stages. RA Capital's existing-investor follow-on signals continued conviction in Acumen's clinical and platform trajectory. ADAR1 Capital Management is a life sciences investment firm focused on biopharmaceutical equities. Sands Capital is a growth-equity firm that broadly backs high-growth public and private companies; their participation alongside the healthcare-specialist funds suggests crossover investor interest. A fourth undisclosed large investment management firm also participated. Companies seeking investment from RA Capital should note that the firm evaluates both clinical-stage risk and platform defensibility, and typically enters positions early in programs it views as having structural differentiation; the EBD program's TfR-targeting angle was likely the key platform rationale alongside sabirnetug's Phase 2 data.

BBB Delivery Platform — Lunai Bioworks

Lunai Bioworks (NASDAQ: LNAI) is an AI-driven life sciences company advancing drug discovery through integrated machine learning, clinical data, and in vivo validation platforms, focused on CNS diseases and oncology. On March 26, 2026, Lunai announced a $20 million strategic transaction to acquire a blood-brain barrier delivery platform and CNS Alzheimer's drug assets from the Clemann Group, SAS. ^[6]

$20M Acquisition: Prodrug BBB delivery chemistry + CNS AD assets; fixed Series B conversion at $1.50/share

The transaction is structured as Series B Convertible Preferred Stock at a fixed conversion price of $1.50 per share with a 19.9% beneficial ownership cap and no variable pricing or reset provisions. The acquired platform uses prodrug-based chemistry: compounds cross the blood-brain barrier in an inactive form and activate specifically inside the brain, targeting acetylcholinesterase modulation pathways broadly implicated in neurological disease. Lunai characterized the acquisition as pairing its AI-driven target identification capabilities with a validated CNS delivery mechanism for its Alzheimer's pipeline.

The Lunai transaction, occurring in the same reporting period as Acumen's EBD financing and NHP data, marks a notable convergence: two companies addressing BBB delivery problems for AD in the same two-week window through mechanistically distinct approaches. However, the two events differ structurally in a way that matters for competitive intelligence purposes. Acumen's event was a capital raise, with external institutional investors providing $35.75M in new cash. Lunai's event was an asset acquisition, with Lunai issuing its own equity (Series B Convertible Preferred at $1.50/share) to the Clemann Group in exchange for their platform and drug assets. No external investor provided capital to Lunai; the Clemann Group received Lunai shares. There is therefore no investor to approach from the Lunai transaction. Lunai's disclosed program is also substantially earlier-stage than Acumen's: no IND timeline was provided, specific drug candidates were not named, and the Clemann Group is not a previously profiled entity in the public AD pipeline.

Competitive Intelligence Highlights

1. EBD/TfR-Targeting Approaches Signal a New Competitive Front in Anti-Amyloid Delivery

The Acumen EBD financing and NHP data disclosure marks the opening of what may become a distinct competitive dimension in anti-amyloid antibody development: not just which epitope to target, but how much of the antibody reaches the brain. ^[1] The 14–40x brain exposure enhancement in NHPs, if reproducible in humans, would reframe dosing and safety calculations for the entire anti-amyloid class. The TfR-mediated BBB delivery field has a relevant historical precedent: bispecific TfR-targeting antibodies have previously demonstrated brain exposure gains in NHPs but caused dose-dependent anemia in humans at exposures required for therapeutic activity. Acumen's explicit disclosure of clean NHP hematology data (no adverse effects observed) is strategically timed to preempt this concern. With an IND targeted for mid-2027, the EBD program is 1–2 years behind the clinical readouts expected from sabirnetug and PMN310, but it enters a landscape where anti-amyloid safety and efficacy benchmarks will be considerably better defined. Separately, Lunai Bioworks' $20 million acquisition of a prodrug-based BBB delivery platform for AD in the same reporting period signals that interest in CNS delivery innovation extends beyond antibody formats to small-molecule chemistry, with two distinct technical approaches converging on the same access problem. ^[6]

2. The Anavex Withdrawal Exposes the Regulatory Risk of Mechanism-Agnostic Endpoints in Neurodegeneration

The EMA's CHMP declining to issue a positive opinion for blarcamesine is a meaningful signal for the broader field of neurodegeneration programs that do not rely on amyloid or tau as primary mechanistic anchors. ^[2] SIGMAR1 engagement does not have an established biomarker footprint that regulators have validated, and blarcamesine's Phase 2b/3 design did not include a biomarker-driven enrichment strategy analogous to what the approved anti-amyloid antibodies (amyloid PET/CSF) are using. The CHMP's feedback, described by Anavex as "constructive," likely reflects questions about whether observed clinical signals are mechanistically attributable to SIGMAR1 modulation. For developers of novel-mechanism CNS therapies, this outcome reinforces the strategic importance of building validated biomarker bridges between target engagement and clinical outcome into trial design before initiating pivotal studies.

3. The PRECISE-AD Trial Is Setting Up the First Direct Test of Whether Avoiding Plaque Binding Eliminates ARIA

PMN310's non-plaque-binding design is a direct competitive response to the ARIA burden that has complicated the commercial rollout of lecanemab and donanemab. ^[5] PRECISE-AD is powered specifically for 95% confidence in ARIA detection, a study design that will yield a definitive answer on the ARIA question regardless of whether top-line efficacy is positive. If PMN310 demonstrates equivalent or superior biological activity to plaque-binding antibodies while producing materially lower ARIA rates, it would validate a new design principle for the next generation of anti-amyloid antibodies and potentially reopen the efficacy/safety trade-off debate for the entire class. The six-month blinded safety and biomarker readout in Q3 2026 will be the first data point on this question and is worth closely tracking.

4. The AD/PD 2026 Conference Revealed a Clear Mechanistic Divide in Patient Enrichment Strategy

The conference-derived events in this period show a converging view: the field is moving toward biomarker-defined patient populations as a precondition for demonstrating efficacy, but the relevant biomarkers differ sharply by mechanism. Annovis is selecting pTau217-positive patients for buntanetap. ^[4] ProMIS is using amyloid confirmation (MCI/mild AD staging) but differentiating on ARIA safety rather than efficacy enrichment. ^[5] The practical implication: any comparative program planning in this space must account for the fact that "Alzheimer's disease" is no longer a single patient population from a regulatory or clinical development standpoint, and that programs targeting overlapping biology (amyloid, tau, neuroinflammation) may be enrolling meaningfully different patients.

5. PrimeC's Imminent AD Readout Is the Most Mechanistically Distinct Data Event on the Near-Term Horizon

NeuroSense's disclosure that PrimeC clinical and biomarker results from its Alzheimer's disease study are expected in the coming weeks creates a near-term watch item. ^[7] PrimeC targets neuron degeneration, inflammation, iron accumulation, and impaired RNA regulation, a multi-mechanistic approach that is distinct from the amyloid-clearance and tau-targeting mechanisms driving the majority of current AD development programs. If the AD data show meaningful clinical or biomarker signal, PrimeC enters the development conversation as a mechanistically differentiated candidate. The same announcement also included a Health Canada pre-NDS rescheduling for PrimeC's ALS program, covered separately under Regulatory Updates.

6. Troculeucel's Phase 1 Results in Moderate AD Create a Potential Differentiation Wedge

The moderate AD population is largely unaddressed by currently approved and late-stage therapies: lecanemab and donanemab were approved for early AD (MCI/mild), and their ongoing post-approval studies have not yet produced data supporting expansion to moderate disease. ^[3] NKGen's Phase 1 data, while open-label and small, show biological activity precisely in the population that approved and late-stage amyloid therapies are not targeting. If the Phase 2 trial replicates dose-responsive cognitive signals with a control arm, troculeucel would be competing in a largely uncontested indication space rather than head-to-head with lecanemab or donanemab. The GFAP biomarker correlations, if they hold in Phase 2, also offer a practical advantage: a blood-based, commercially available test that tracks clinical response would reduce the biomarker infrastructure burden on trial sites and eventual commercial prescribers.

Concluding Remarks

This reporting period was anchored by the AD/PD™ 2026 conference (March 17–21, Copenhagen), which generated two of the six events alongside four separate corporate disclosures. Activity spanned all four event categories (data readouts, trial updates, a regulatory setback, and funding/BD), reflecting the full breadth of pipeline activity typical of a major conference reporting period.

Data readout activity produced the most clinically immediate findings. NKGen's Phase 1 pooled analysis for troculeucel in moderate AD (100% of patients stable or improved, 50% transitioning from moderate to mild on CDR-SB, consistent plasma GFAP biomarker correlations) represents a signal in a population currently unaddressed by approved therapies. Lecanemab and donanemab were approved for early AD; the moderate disease space remains effectively open, and troculeucel's ongoing Phase 2 controlled trial will be the first randomized test of whether these open-label signals hold.

Trial activity was defined by enrollment milestones rather than efficacy data, but the operational signals are meaningful. Buntanetap's dual-readout Phase 3 design (symptomatic endpoint at 6 months, disease-modification at 18 months) is structurally innovative and will generate multiple decision points on the same trial timeline. ProMIS's PRECISE-AD overenrollment (144 vs. 128 participants) and DSMB clearance to the highest dose level set up a Q3 2026 safety and biomarker readout: the first clinical test of whether non-plaque-binding anti-amyloid antibodies can eliminate ARIA while preserving biological activity.

Regulatory activity produced two events. The EMA withdrawal for blarcamesine is the primary AD-specific regulatory event: CHMP declined to issue a positive opinion, illustrating the risk facing programs that lack validated mechanistic biomarkers. The second event, NeuroSense's Health Canada pre-NDS rescheduling, pertains to PrimeC's ALS program; it is covered here because PrimeC is the same asset in active AD development, and its ALS regulatory trajectory has direct bearing on the compound's overall development posture. Together, both events reinforce the trend visible across trial-stage programs this period (pTau217 enrichment for buntanetap, amyloid confirmation for PMN310) that biomarker-anchored regulatory strategy is increasingly the expectation, not a differentiator.

Funding and BD activity featured two structurally distinct transactions. Acumen's $35.75M private placement, led by existing investor RA Capital, signals continued institutional conviction in BBB delivery and AβO targeting as a platform strategy. Lunai's $20M transaction is an asset acquisition, not a capital raise; equity was issued to the seller rather than received from an investor. Both events reflect convergent strategic interest in CNS access as a differentiation vector in the AD space, but only Acumen's financing carries actionable investor intelligence.

The AD pipeline continues to diversify beyond the approved amyloid-clearance class. The programs in this period (NK cell immunotherapy, translation inhibition, oligomer-selective antibody targeting, sigma-1 receptor modulation, BBB delivery engineering, and multi-mechanistic combination pharmacology) reflect a field pursuing protein clearance, upstream immune modulation, drug delivery innovation, and systems-level pathway targeting as complementary vectors of progress. NeuroSense's impending PrimeC AD readout adds a near-term data watch point in the coming weeks that could introduce the first fixed-dose combination approach to the AD development landscape.

Methodology and Sources

This report covers the period March 16, 2026 through March 31, 2026. Events were identified through systematic monitoring of SEC EDGAR 8-K filings, company press releases, conference abstract publications, and corporate financial disclosures from publicly traded clinical-stage biotechnology and pharmaceutical companies with active programs in Alzheimer's disease and related dementias. The majority of events in this period were disclosed in conjunction with the AD/PD™ 2026 International Conference on Alzheimer's and Parkinson's Diseases (March 17–21, Copenhagen, Denmark). Source documents were reviewed in full; conference abstracts were treated as equivalent primary sources to press releases for events originating from AD/PD 2026. Payer and market access analysis is outside the scope of this edition.

The report covers eight events across seven companies (Acumen Pharmaceuticals, Anavex Life Sciences, NKGen Biotech, Annovis Bio, ProMIS Neurosciences, Lunai Bioworks, NeuroSense Therapeutics). The primary indication is Alzheimer's Disease; one event (NeuroSense's Health Canada pre-NDS rescheduling) relates to PrimeC's ALS program and is included because the same asset is in active AD development. Both positive developments and regulatory setbacks are covered with equivalent analytical depth.

References

[1] "Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio." Acumen Pharmaceuticals, Inc. / SEC EDGAR EX-99.1, March 16, 2026. Link

[2] "Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease." Anavex Life Sciences Corp. / SEC EDGAR EX-99.1, March 25, 2026. Link

[3] "NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer's Disease at AD/PD 2026™." NKGen Biotech, Inc. / GlobeNewswire, March 23, 2026. Link

[4] "A Dual 6-Month & 18-Month Randomized, Placebo-Controlled, Double-Blind, Clinical Trial Investigating Efficacy and Safety of Buntanetap in Early Alzheimer's Participants." Annovis Bio / AD/PD™ 2026 Abstract #3582, March 19, 2026. Link

[5] "ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights." ProMIS Neurosciences Inc. / GlobeNewswire, March 25, 2026. Link

[6] "Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications." Lunai Bioworks Inc. / PRNewswire, March 26, 2026. Link

[7] "NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout." NeuroSense Therapeutics Ltd. / PRNewswire, March 24, 2026. Link